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Background: Bisphosphonates have been associated with an increased risk of serious atrial fibrillation (AF). We determined the effects of 
zoledronic acid (ZA) on atrial measures associated with AF.
methods: Ex vivo study: Hearts from Dunkin-Hartley (D-H) guinea pigs (n=12) were excised and randomized to perfusion with modified Krebs-
Henseleit (K-H) buffer and ZA 0.07 mg/kg or K-H without ZA. Left atrial monophasic action potentials (MAPs) were recorded at 240 bpm for 20 
minutes.
In vivo chronic ZA: D-H guinea pigs (n=32) were randomized to intraperitoneal injections every 2 weeks in one of 4 groups: ZA 0.007 mg/kg (low), ZA 
0.07 mg/kg (therapeutic), ZA 0.7 mg/kg (high dose), or placebo. Hearts were excised at 8 weeks and perfused with modified K-H. Left atrial MAPs 
and effective refractory periods (ERP) were measured.
results: Ex vivo study: ZA-perfused hearts showed a decrease from baseline in atrial action potential duration at 90% repolarization (APD90)vs 
controls (-23.2% ± -5.1% vs -2.1% ± -9.1%, p < 0.0001) and APD30 (-18.8% ± -4.9% vs -1.9% ± -8.7%, p<0.0001).
In vivo chronic ZA: Atrial ERP and APD30 were decreased by ZA (Table; data are mean±SD). There were significant differences in ERP between placebo 
and therapeutic dose groups and between placebo and high dose groups. There were significant differences in APD30 between the placebo and high 
dose group; low and high dose group; and therapeutic and high dose group.
conclusion: ZA shortens left atrial APD and ERP, which may result in an increased risk of AF.
Effects of ZA on Atrial Electrophysiology
Placebo Low Dose ZA Therapeutic Dose ZA High Dose ZA p
ERP (ms) 106.0 ± 15.9 94.4 ± 12.4 83.1 ± 7.8* 87.1 ± 10.6* 0.004
APD90 (ms) 90.1 ± 13.0 90.1 ± 10.4 85.4 ± 9.6 77.2 ± 9.6 0.08
APD30 (ms) 59.2 ± 6.9 62.6 ± 6.4 57.2 ± 7.5 46.7 ± 6.4*† <0.0001
*p<0.05 vs placebo
*p<0.05 vs placebo
†p<0.05 vs low and therapeutic dose
